Thomas Delea

Summary

Affiliation: Policy Analysis Inc
Country: USA

Publications

  1. ncbi Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders
    Thomas E Delea
    Policy Analysis Inc PAI, Brookline, MA 02445, USA
    Curr Med Res Opin 25:139-47. 2009
  2. pmc Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma
    T E Delea
    PAI Policy Analysis Inc, 4 Davis Court, Brookline, MA 02445, USA
    Br J Cancer 107:1059-68. 2012
  3. ncbi Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab
    Thomas E Delea
    Policy Analysis Inc PAI, Four Davis Court, Brookline, MA 02445, USA
    Eur J Health Econ 13:589-603. 2012
  4. doi Cost-effectiveness of zoledronic acid vs clodronic acid for newly-diagnosed multiple myeloma from the United Kingdom healthcare system perspective
    Thomas E Delea
    PAI Policy Analysis Inc Brookline, MA, USA
    J Med Econ 15:454-64. 2012
  5. ncbi Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective
    Thomas E Delea
    Policy Analysis Inc PAI, Brookline, MA 02445, USA
    Breast Cancer Res Treat 108:375-87. 2008
  6. ncbi Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review
    Thomas E Delea
    Policy Analysis Inc PAI, Four Davis Court, Brookline, MA 02445 USA
    Transfusion 47:1919-29. 2007
  7. ncbi Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States
    Thomas E Delea
    Policy Analysis Inc PAI, Brookline, MA 02445, USA
    Am J Hematol 83:263-70. 2008
  8. doi Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma
    Thomas E Delea
    Policy Analysis Inc, Brookline, Massachusetts 02445, USA
    Clin Ther 30:560-71. 2008
  9. ncbi Association between adherence with fixed dose combination fluticasone propionate/salmeterol on asthma outcomes and costs*
    Thomas E Delea
    Policy Analysis, Inc, Brookline, MA, USA
    Curr Med Res Opin 24:3435-42. 2008
  10. pmc Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria
    Thomas E Delea
    Policy Analysis, Inc, Brookline, Massachusetts 02445, USA
    J Am Soc Nephrol 20:2205-13. 2009

Detail Information

Publications30

  1. ncbi Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders
    Thomas E Delea
    Policy Analysis Inc PAI, Brookline, MA 02445, USA
    Curr Med Res Opin 25:139-47. 2009
    ..Although red cell transfusions are known to cause iron overload, data on the risk of iron-related complications in these patients are limited...
  2. pmc Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma
    T E Delea
    PAI Policy Analysis Inc, 4 Davis Court, Brookline, MA 02445, USA
    Br J Cancer 107:1059-68. 2012
    ..The relationship between progression-free survival and time to progression (PFS/TTP) and overall survival (OS) has been demonstrated in a variety of solid tumours but not in metastatic renal cell carcinoma (mRCC)...
  3. ncbi Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab
    Thomas E Delea
    Policy Analysis Inc PAI, Four Davis Court, Brookline, MA 02445, USA
    Eur J Health Econ 13:589-603. 2012
    ....
  4. doi Cost-effectiveness of zoledronic acid vs clodronic acid for newly-diagnosed multiple myeloma from the United Kingdom healthcare system perspective
    Thomas E Delea
    PAI Policy Analysis Inc Brookline, MA, USA
    J Med Econ 15:454-64. 2012
    ....
  5. ncbi Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective
    Thomas E Delea
    Policy Analysis Inc PAI, Brookline, MA 02445, USA
    Breast Cancer Res Treat 108:375-87. 2008
    ....
  6. ncbi Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review
    Thomas E Delea
    Policy Analysis Inc PAI, Four Davis Court, Brookline, MA 02445 USA
    Transfusion 47:1919-29. 2007
    ..Deferasirox is a once-daily oral iron chelator that was approved in the United States in 2005 for patients older than 2 years of age with transfusional iron overload...
  7. ncbi Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States
    Thomas E Delea
    Policy Analysis Inc PAI, Brookline, MA 02445, USA
    Am J Hematol 83:263-70. 2008
    ..Administration costs represent a large proportion of the cost of chelation therapy. Potential complications of iron overload are associated with increased costs...
  8. doi Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma
    Thomas E Delea
    Policy Analysis Inc, Brookline, Massachusetts 02445, USA
    Clin Ther 30:560-71. 2008
    ....
  9. ncbi Association between adherence with fixed dose combination fluticasone propionate/salmeterol on asthma outcomes and costs*
    Thomas E Delea
    Policy Analysis, Inc, Brookline, MA, USA
    Curr Med Res Opin 24:3435-42. 2008
    ..To assess the association between adherence with fluticasone propionate/salmeterol combination (FSC) product in a single inhaler and asthma care utilization and costs in asthma patients in typical US clinical practice...
  10. pmc Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria
    Thomas E Delea
    Policy Analysis, Inc, Brookline, Massachusetts 02445, USA
    J Am Soc Nephrol 20:2205-13. 2009
    ..In conclusion, adding aliskiren to losartan and optimal therapy in patients with type 2 diabetes, hypertension, and albuminuria may be cost-effective from a US health care system perspective...
  11. ncbi Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease
    Thomas E Delea
    Policy Analysis Inc, Brookline, MA 02245, USA
    Curr Med Res Opin 26:1543-52. 2010
    ....
  12. doi Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer
    Thomas E Delea
    Policy Analysis Inc, Brookline, MA 02445, USA
    Clin Breast Cancer 10:267-74. 2010
    ....
  13. doi The association between adherence to levodopa/carbidopa/entacapone therapy and healthcare utilization and costs among patients with Parkinson's disease: a retrospective claims-based analysis
    Thomas E Delea
    PAI Policy Analysis, Inc, Brookline, Massachusetts 02445, USA
    CNS Drugs 25:53-66. 2011
    ..Suboptimal adherence to long-term therapies is common and may potentially have adverse consequences on patient outcomes and healthcare costs...
  14. ncbi Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer
    Thomas E Delea
    Policy Analysis Inc, Brookline, MA 02445, USA
    Clin Breast Cancer 7:608-18. 2007
    ....
  15. ncbi Valsartan versus lisinopril or extended-release metoprolol in preventing cardiovascular and renal events in patients with hypertension
    Thomas E Delea
    Policy Analysis Inc, Brookline, MA 02245, USA
    Am J Health Syst Pharm 64:1187-96. 2007
    ....
  16. ncbi Administrative claims analysis of utilization and costs of care in health plan members with atopic dermatitis who had prior use of a topical corticosteroid and who initiate therapy with pimecrolimus or tacrolimus
    Thomas E Delea
    Policy Analysis Inc, Brookline, Massachusetts 02445, USA
    J Manag Care Pharm 13:349-59. 2007
    ..Comparative data on the effects of pimecrolimus versus tacrolimus on AD-related health care utilization and costs among similar patients seen in typical clinical practice are currently unavailable...
  17. ncbi The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer
    Thomas Delea
    Policy Analysis Inc PAI, Brookline, Mass, USA
    Oncology 67:390-6. 2004
    ..These complications result in impaired mobility and reduced quality of life and have a significant negative impact on survival. The economic consequences of SREs in patients with lung cancer have not been examined...
  18. ncbi Death and hospitalization in heart failure patients receiving carvedilol vs. metoprolol tartrate
    Thomas E Delea
    Policy Analysis Inc PAI, Four Davis Court, Brookline, MA 02445, USA
    Int J Cardiol 99:117-24. 2005
    ..metoprolol tartrate in patients with heart failure. The benefits of carvedilol in typical clinical practice in the United States are unknown...
  19. ncbi Cost-effectiveness of fluvastatin following successful first percutaneous coronary intervention
    Thomas E Delea
    Policy Analysis Inc PAI, Brookline, MA 02245 7629, USA
    Ann Pharmacother 39:610-6. 2005
    ..01) following successful first percutaneous coronary intervention (PCI) in patients with stable or unstable angina or silent ischemia. The cost-effectiveness of such therapy is unknown...
  20. ncbi Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer
    Thomas E Delea
    Policy Analysis Inc, 4 Davis Court, Brookline, MA 02245, USA
    Am J Manag Care 12:374-86. 2006
    ..To estimate the cost-effectiveness of extended adjuvant letrozole in postmenopausal women with early breast cancer and estrogen or progesterone receptor-positive tumors who had completed 5 years of adjuvant tamoxifen...
  21. ncbi Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice
    Thomas Delea
    Policy Analysis Inc PAI, Brookline, Massachusetts 02245 7629, USA
    J Support Oncol 4:341-7. 2006
    ..Treatments that reduce the incidence of SREs, such as intravenous bisphosphonates, should reduce these costs...
  22. ncbi Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective
    Thomas E Delea
    Policy Analysis Inc PAI, Brookline, Massachusetts 02445, USA
    Pharmacoeconomics 25:329-42. 2007
    ..Deferasirox is a recently approved once-daily oral iron chelator that has been shown to reduce liver iron concentrations and serum ferritin levels to a similar extent as infusional deferoxamine...
  23. ncbi Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer
    Thomas E Delea
    Policy Analysis Inc, Brookline, MA 02445, USA
    J Thorac Oncol 1:571-6. 2006
    ..This approach may underestimate costs if SREs indirectly increase use of other services...
  24. ncbi Healthcare use and costs in patients with chronic bronchitis initiating maintenance therapy with fluticasone/salmeterol vs other inhaled maintenance therapies
    Thomas E Delea
    Policy Analysis Inc PAI, Brookline, MA, USA
    Curr Med Res Opin 25:1-13. 2009
    ....
  25. ncbi The incidence and cost of hospitalization for 5-FU toxicity among Medicare beneficiaries with metastatic colorectal cancer
    Thomas E Delea
    Policy Analysis Inc PAI, 4 Davis Court, Brookline, MA 02245, USA
    Value Health 5:35-43. 2002
    ..To estimate the incidence and associated cost of hospitalizations for toxicities associated with 5-fluorouracil (5-FU) among patients with metastatic colorectal cancer...
  26. ncbi Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study
    Thomas E Delea
    Policy Analysis, Brookline, Massachusetts 02455, USA
    Diabetes Care 26:2983-9. 2003
    ..To compare the incidence of heart failure in individuals with type 2 diabetes receiving thiazolidinediones (TZDs) versus other oral antihyperglycemic agents...
  27. ncbi Treatment of peripheral neuropathic pain: a simulation model
    Montserrat Vera-Llonch
    Policy Analysis Inc, Four Davis Court, Brookline, MA 02445, United States
    Eur J Pain 10:279-85. 2006
    ..To describe the use of a generalizable stochastic-simulation model of the treatment of neuropathic pain associated with peripheral neuropathies...
  28. ncbi Therapy switching in patients receiving long-acting opioids
    Ariel Berger
    Policy Analysis Inc, Brookline, MA 02445 7629, USA
    Ann Pharmacother 38:389-95. 2004
    ..Patterns of therapy switching in patients receiving long-acting opioids have not been well documented...
  29. ncbi Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model
    Montserrat Vera-Llonch
    Policy Analysis Inc PAI, Brookline, MA 02445, USA
    Value Health 7:569-84. 2004
    ..To compare expected outcomes and costs of care in patients with chronic schizophrenia or schizoaffective disorders who are treated with risperidone versus olanzapine...
  30. ncbi Use of oral antithrombotic agents among health maintenance organization members with atherosclerotic cardiovascular disease
    Jonathan B Brown
    Center for Health Research, 3800 N Interstate Ave, Portland, OR 97227 1110, USA
    Arch Intern Med 162:193-9. 2002
    ..Although antithrombotic agents are often prescribed at hospital discharge after CVD-related events, much less is known about the ongoing use of such agents...